Nitrosamine impurities in medications: Recalls
On this page
- What you should do
- ARB recalls
- Ranitidine recalls
- Nizatidine recalls
- Metformin recalls
- Varenicline recalls
- Orphenadrine recalls
- Amitriptyline recalls
- Propranolol recalls
- Quinapril recalls
- Acyclovir recalls
- Duloxetine recalls
What you should do
If a drug is recalled, you shouldn't stop taking your prescription medications until you:
- talk to your health care provider first and
- obtain an alternative treatment
Going without treatment for a medical condition may pose a greater health risk than potential nitrosamine exposure.
Speak to your pharmacist to see if the lot of medication you're taking is part of the recall.
You're encouraged to report a side effect to a drug or complaint to Health Canada.
ARBs recalls
Sartans or angiotensin II receptor blockers (ARBs)
If you're taking an ARB that has been recalled, you should:
- Continue taking your medication unless your health care provider has advised you to stop.
- Contact your health care provider:
- to discuss treatment options if you're using a recalled product
- if you have taken a recalled product in the past and are concerned about your health
Some ARBs have been recalled due to the presence of, or potential for, nitrosamine impurities.
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not affect Canadian products.
Product name | DIN | Strength | Lot # | Date recalled | API manufacturer |
---|---|---|---|---|---|
AURO-IRBESARTAN/HCT | 02447878 | 150/12.5 mg | IN1518001-A | April 17, 2019 | Aurobindo Pharma Limited, Unit-I |
IRBESARTAN (PRO DOC LIMITEE) | 02365200 | 150 mg | 604292 | March 11, 2019 | TEVA API India Ltd. |
IRBESARTAN (PRO DOC LIMITEE) | 02365219 | 300 mg | 601795 | March 11, 2019 | TEVA API India Ltd. |
APO-LOSARTAN | 02379058 | 25 mg | NL1453 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN | 02379058 | 25 mg | NL1452 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN | 02353504 | 50 mg | NK1254 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN | 02353504 | 50 mg | NK1253 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN | 02353512 | 100 mg | NL1461 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN | 02353512 | 100 mg | NG2092 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN | 02353512 | 1 00 mg | NH5932 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN | 02353512 | 100 mg | NH5933 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN | 02353512 | 100 mg | NL1460 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN | 02353512 | 100 mg | NH5934 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371235 | 50/12.5 mg | NL1441 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371235 | 50/12.5 mg | NZ8848 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371235 | 50/12.5 mg | NL1445 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371235 | 50/12.5 mg | NZ8849 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371235 | 50/12.5 mg | NZ8860 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371243 | 100/12.5 mg | NG2087 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371243 | 100/12.5 mg | NL1421 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371243 | 100/12.5 mg | NG2086 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371243 | 100/12.5 mg | NL1422 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371251 | 100/25 mg | NL1429 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371251 | 100/25 mg | NZ8846 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371251 | 100/25 mg | NZ8847 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
APO-LOSARTAN/HCTZ | 02371251 | 100/25 mg | NZ8845 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309750 | 25 mg | 498294 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309750 | 25 mg | 605342 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309750 | 25 mg | 611944 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309769 | 50 mg | 498285 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309769 | 50 mg | 600047 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309769 | 50 mg | 600091 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309769 | 50 mg | 603894 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309769 | 50 mg | 612025 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309769 | 50 mg | 612031 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309769 | 50 mg | 612679 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309769 | 50 mg | 616743 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309777 | 100 mg | 498864 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309777 | 100 mg | 602668 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309777 | 100 mg | 603816 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309777 | 100 mg | 605298 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309777 | 100 mg | 605300 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309777 | 100 mg | 613935 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
PMS-LOSARTAN | 02309777 | 100 mg | 613936 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
LOSARTAN (PRO DOC LIMITEE) | 02394367 | 25 mg | 498292 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
LOSARTAN (PRO DOC LIMITEE) | 02394367 | 25 mg | 605344 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
LOSARTAN (PRO DOC LIMITEE) | 02394375 | 50 mg | 498779 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
LOSARTAN (PRO DOC LIMITEE) | 02394375 | 50 mg | 600046 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
LOSARTAN (PRO DOC LIMITEE) | 02394375 | 50 mg | 603903 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
LOSARTAN (PRO DOC LIMITEE) | 02394375 | 50 mg | 498284 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
LOSARTAN (PRO DOC LIMITEE) | 02394375 | 50 mg | 603895 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
LOSARTAN (PRO DOC LIMITEE) | 02394383 | 100 mg | 499008 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
LOSARTAN (PRO DOC LIMITEE) | 02394383 | 100 mg | 605299 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
LOSARTAN (PRO DOC LIMITEE) | 02394383 | 100 mg | 605297 | March 8, 2019 | Hetero Laboratories Limited Unit 1 |
TEVA-LOSARTAN/HCTZ | 02358263 | 50/12.5 mg | 35344801A | March 6, 2019 | Hetero Laboratories Limited Unit 1 |
TEVA-LOSARTAN/HCTZ | 02358263 | 50/12.5mg | 35349397A | March 6, 2019 | Hetero Laboratories Limited Unit 1 |
MYLAN-VALSARTAN | 02383527 | 40 mg | All lots | November 28, 2018 | Mylan Laboratories Limited |
MYLAN-VALSARTAN | 02383535 | 80 mg | All lots | November 28, 2018 | Mylan Laboratories Limited |
MYLAN-VALSARTAN | 02383543 | 160 mg | All lots | November 28, 2018 | Mylan Laboratories Limited |
MYLAN-VALSARTAN | 02383551 | 3 20 mg | All lots | November 28, 2018 | Mylan Laboratories Limited |
TEVA-VALSARTAN/HCTZ TABLETS | 02356996 | 80/12.5 mg | 35211136A | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
TEVA-VALSARTAN/HCTZ TABLETS | 02357003 | 160/12.5 mg | 35211335A | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
TEVA-VALSARTAN/HCTZ TABLETS | 02357003 | 160/12.5 mg | 35211844R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
TEVA-VALSARTAN/HCTZ TABLETS | 02357011 | 160/25 mg | 35210937R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
TEVA-VALSARTAN/HCTZ TABLETS | 02357011 | 160/25 mg | 35210938R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
TEVA-VALSARTAN/HCTZ TABLETS | 02357011 | 160/25 mg | 35210939R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
TEVA-VALSARTAN/HCTZ TABLETS | 02357011 | 160/25 mg | 35210940R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
TEVA-VALSARTAN/HCTZ TABLETS | 02357038 | 3 20/12.5 mg | 35211546R | August 17, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337487 | 40 mg | K47338 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337495 | 80 mg | K45370 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337495 | 80 mg | K47652 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337495 | 80 mg | K47653 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337495 | 80mg | K47654 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337509 | 160 mg | K39691 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337509 | 160 mg | K44167 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337509 | 160 mg | K47657 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337509 | 160 mg | K47658 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337517 | 320 mg | K44166 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
ACT-VALSARTAN | 02337517 | 320 mg | K45371 | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
VALSARTAN (PRO DOC LIMITEE) | 02367726 | 40 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
VALSARTAN (PRO DOC LIMITEE) | 02367734 | 80 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
VALSARTAN (PRO DOC LIMITEE) | 02367742 | 160 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
VALSARTAN (PRO DOC LIMITEE) | 02367750 | 320 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
SANDOZ VALSARTAN | 02356740 | 40 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
SANDOZ VALSARTAN | 02356759 | 80 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
SANDOZ VALSARTAN | 02356767 | 160 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
SANDOZ VALSARTAN | 02356775 | 320 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
SANIS VALSARTAN | 02366940 | 40 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
SANIS VALSARTAN | 02366959 | 80 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
SANIS VALSARTAN | 02366967 | 160 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
SANIS VALSARTAN | 02366975 | 320 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
VALSARTAN (SIVEM PHARMACEUTICAL ULC) | 02384523 | 40 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
VALSARTAN (SIVEM PHARMACEUTICAL ULC) | 02384531 | 80 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
VALSARTAN (SIVEM PHARMACEUTICAL ULC) | 02384558 | 160 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
VALSARTAN (SIVEM PHARMACEUTICAL ULC) | 02384566 | 320 mg | All lots | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
TEVA-VALSARTAN/HCTZ | 02357046 | 320/25 mg | 35212731R | July 9, 2018 | Zhejiang Huahai Pharmaceuticals |
Communications related to ARB recalls:
- Auro Pharma Inc. voluntarily recalls one lot of Auro-Irbesartan HCT tablets because of nitrosamine impurity (information update April 4, 2019)
- Pro Doc Limitée voluntarily recalls two lots of irbesartan drugs because of nitrosamine impurity (information update, March 14, 2019)
- Multiple Losartan-containing drugs voluntarily recalled because of potential for nitrosamine impurity (information update March 9, 2019)
- Health Canada releases test results of certain sartan drugs (information update December 20, 2018)
- Mylan-Valsartan medications voluntarily recalled as a precaution due to an impurity (information update November 28, 2018)
- Health Canada finds Zhejiang Huahai Pharmaceuticals site non-compliant with requirements for the manufacture of drug ingredients (information update October 2, 2018)
- Health Canada advises of a second impurity linked to recalled valsartan drugs (information update September 13, 2018)
- Health Canada updates Canadians on estimates of health risks for recalled valsartan drugs containing NDMA (information update September 10, 2018)
- Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution (information update August 18, 2018)
- Several drugs containing valsartan being recalled due to contamination with a potential carcinogen (advisory July 9, 2018)
Ranitidine recalls
Ranitidine
If you're taking a ranitidine product, you should:
- Talk to your doctor or pharmacist as soon as you can about non-ranitidine treatment options that are right for you.
- Many alternative prescription and over-the-counter drug options in Canada have the same or similar uses as ranitidine.
- Continue taking your prescription or over-the-counter ranitidine drug, even if it has been recalled, unless you have obtained alternative treatment from your health care provider.
- The risk of not treating your condition may be greater than the risk from NDMA exposure.
- Contact your health care provider if you have taken a ranitidine product and have concerns about your health.
Some ranitidine products have been recalled due to the presence of or potential for nitrosamine impurities
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not affect Canadian products.
The following ranitidine products have been recalled in Canada.
Company | Product name | DIN | Strength | Lot | Date added |
---|---|---|---|---|---|
Pharmascience Inc. | ATOMA maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744F | 2022-03-11 |
Pharmascience Inc. | ATOMA maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632058H | 2022-03-11 |
Pharmascience Inc. | Compliments maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043B | 2022-03-11 |
Pharmascience Inc. | Compliments maximum strength acid reducer without prescription cool mint (24 tablets) | 02293471 | 150 mg | 629973A | 2022-03-11 |
Pharmascience Inc. | CO-OP Care+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744C | 2022-03-11 |
Pharmascience Inc. | Health One maximum strength acid reducer without prescription (32 tablets) | 02293471 | 150 mg | 629744J | 2022-03-11 |
Pharmascience Inc. | Health One maximum strength acid reducer without prescription (32 tablets) | 02293471 | 150 mg | 632043H | 2022-03-11 |
Pharmascience Inc. | Life Brand maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744H | 2022-03-11 |
Pharmascience Inc. | Life Brand maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632058I | 2022-03-11 |
Pharmascience Inc. | Life Brand maximum strength acid reducer without prescription cool mint (48 tablets) | 02293471 | 150 mg | 629974B | 2022-03-11 |
Pharmascience Inc. | Life Brand maximum strength acid reducer without prescription cool mint (24 tablets) | 02293471 | 150 mg | 629974A | 2022-03-11 |
Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744G | 2022-03-11 |
Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043D | 2022-03-11 |
Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043E | 2022-03-11 |
Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 632058A | 2022-03-11 |
Pharmascience Inc. | Option+ maximum strength acid reducer without prescription cool mint (24 tablets) | 02293471 | 150 mg | 629973B | 2022-03-11 |
Pharmascience Inc. | Option+ maximum strength acid reducer without prescription cool mint (24 tablets) | 02293471 | 150 mg | 631893C | 2022-03-11 |
Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744E | 2022-03-11 |
Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043A | 2022-03-11 |
Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043F | 2022-03-11 |
Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632058J | 2022-03-11 |
Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 629744B | 2022-03-11 |
Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 632058B | 2022-03-11 |
Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription cool mint (24 tablets) | 02293471 | 150 mg | 629973C | 2022-03-11 |
Pharmascience Inc. | PERSONNELLE maximum strength acid reducer without prescription cool mint (48 tablets) | 02293471 | 150 mg | 629973D | 2022-03-11 |
Pharmascience Inc. | PHARMASAVE maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 629744A | 2022-03-11 |
Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 629744I | 2022-03-11 |
Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632043G | 2022-03-11 |
Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 632058G | 2022-03-11 |
Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 632058D | 2022-03-11 |
Pharmascience Inc. | BIOMEDIC Acid Reducer (30 tablets) | 02247551 | 75 mg | 632952I | 2021-12-03 |
Pharmascience Inc. | Life Brand Acid Reducer (30 tablets) | 02247551 | 75 mg | 632952K | 2021-12-03 |
Pharmascience Inc. | OPTION+ Acid Reducer (10 tablets) | 02247551 | 75 mg | 632952B | 2021-12-03 |
Pharmascience Inc. | OPTION+ Acid Reducer (40 tablets) | 02247551 | 75 mg | 633694B | 2021-12-03 |
Pharmascience Inc. | Personnelle Acid Reducer (10 tablets) | 02247551 | 75 mg | 632952D | 2021-12-03 |
Pharmascience Inc. | ATOMA maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765H | 2021-12-03 |
Pharmascience Inc. | BIOMEDIC maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765I | 2021-12-03 |
Pharmascience Inc. | BIOMEDIC maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 628471C | 2021-12-03 |
Pharmascience Inc. | Compliments maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 628471D | 2021-12-03 |
Pharmascience Inc. | CO-OP Care+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765D | 2021-12-03 |
Pharmascience Inc. | Health One maximum strength acid reducer without prescription (32 tablets) | 02293471 | 150 mg | 628471A | 2021-12-03 |
Pharmascience Inc. | London Drugs maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765E | 2021-12-03 |
Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 627765B | 2021-12-03 |
Pharmascience Inc. | Option+ maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765G | 2021-12-03 |
Pharmascience Inc. | PHARMASAVE maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 627765C | 2021-12-03 |
Pharmascience Inc. | PHARMASAVE maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 628471B | 2021-12-03 |
Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (8 tablets) | 02293471 | 150 mg | 627765A | 2021-12-03 |
Pharmascience Inc. | Rexall maximum strength acid reducer without prescription (24 tablets) | 02293471 | 150 mg | 627765F | 2021-12-03 |
Pharmascience Inc. | Compliments Maximum Strength Acid Reducer (50 tablets) | 02293471 | 150mg | 628453 | 2021-02-05 |
Pharmascience Inc. | CO-OP CARE + Maximum Strength Acid Reducer (24 tablets) | 02293471 | 150mg | 628308F | 2021-02-05 |
Pharmascience Inc. | Life Brand Maximum Strength Acid Reducer (50 tablets) | 02293471 | 150mg | 628429 | 2021-02-05 |
Pharmascience Inc. | Life Brand Maximum Strength Acid Reducer (24 tablets) | 02293471 | 150mg | 628308E | 2021-02-05 |
Pharmascience Inc. | Option+ Maximum Strength Acid Reducer (8 tablets) | 02293471 | 150mg | 628308B | 2021-02-05 |
Pharmascience Inc. | Personnelle Maximum Strength Acid Reducer (50 tablets) | 02293471 | 150mg | 628442 | 2021-02-05 |
Pharmascience Inc. | PERSONNEL Maximum Strength Acid Reducer (8 tablets) | 02293471 | 150mg | 628308A 628308C |
2021-02-05 |
Pharmascience Inc. | PERSONNEL Maximum Strength Acid Reducer (24 tablets) | 02293471 | 150mg | 628308D | 2021-02-05 |
Pharmascience Inc. | pms-RANITIDINE | 02242453 | 150mg | 626718 623633 624871 626714 |
2021-02-05 |
Pharmascience Inc. | ATOMA Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791O | 2021-01-30 |
Pharmascience Inc. | ATOMA Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791X | 2021-01-30 |
Pharmascience Inc. | BIOMEDIC Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791K | 2021-01-30 |
Pharmascience Inc. | BIOMEDIC Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791U | 2021-01-30 |
Pharmascience Inc. | Compliments Acid Reducer (60 tablets) | 02247551 | 75 mg | 621791D | 2021-01-30 |
Pharmascience Inc. | Life Brand Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791G | 2021-01-30 |
Pharmascience Inc. | Life Brand Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791P | 2021-01-30 |
Pharmascience Inc. | Life Brand Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791Q | 2021-01-30 |
Pharmascience Inc. | Life Brand Acid Reducer (60 tablets) | 02247551 | 75 mg | 621791AA | 2021-01-30 |
Pharmascience Inc. | London Drugs Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791R | 2021-01-30 |
Pharmascience Inc. | OPTION+ Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791H | 2021-01-30 |
Pharmascience Inc. | OPTION+ Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791T | 2021-01-30 |
Pharmascience Inc. | OPTION+ Acid Reducer (40 tablets) | 02247551 | 75 mg | 621791Y | 2021-01-30 |
Pharmascience Inc. | Personnelle Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791A | 2021-01-30 |
Pharmascience Inc. | Personnelle Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791N | 2021-01-30 |
Pharmascience Inc. | Personnelle Acid Reducer (40 tablets) | 02247551 | 75 mg | 621791I | 2021-01-30 |
Pharmascience Inc. | Personnelle Acid Reducer (40 tablets) | 02247551 | 75 mg | 621791Z | 2021-01-30 |
Pharmascience Inc. | PHARMASAVE Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791V | 2021-01-30 |
Pharmascience Inc. | Rexall Acid Reducer (60 tablets) | 02247551 | 75 mg | 621791S | 2021-01-30 |
Pharmascience Inc. | Rexall Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791F | 2021-01-30 |
Pharmascience Inc. | Rexall Acid Reducer (10 tablets) | 02247551 | 75 mg | 621791M | 2021-01-30 |
Pharmascience Inc. | Rexall Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791E | 2021-01-30 |
Pharmascience Inc. | Rexall Acid Reducer (30 tablets) | 02247551 | 75 mg | 621791W | 2021-01-30 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Compliments | 02247551 | 75 mg | 619254I | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name EXACT | 02247551 | 75 mg | 619254G | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name EXACT | 02247551 | 75 mg | 619254B | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Life Brand | 02247551 | 75 mg | 624735C | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Life Brand | 02247551 | 75 mg | 627539C | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Life Brand | 02247551 | 75 mg | 619254H | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Life Brand | 02247551 | 75 mg | 619254C | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name OPTION+ | 02247551 | 75 mg | 624735B | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name OPTION+ | 02247551 | 75 mg | 627539B | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Personnelle | 02247551 | 75 mg | 624735A | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Personnelle | 02247551 | 75 mg | 619254K | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name Personnelle | 02247551 | 75 mg | 627539A | 2021-01-08 |
Pharmascience Inc. | Acid Reducer (raniditine) sold under the brand name PHARMASAVE | 02247551 | 75 mg | 619254J | 2021-01-08 |
Pharmascience Inc. | PMS-Ranitidine 150 mg | 02242453 | 150 mg | 619003 | 2020-08-31 |
Ranbaxy Pharmaceuticals Canada Inc. | Ran-Ranitidine | 02336480 | 150 mg | All lots | 2019-10-30 |
Ranbaxy Pharmaceuticals Canada Inc. | Ran-Ranitidine | 02336502 | 300 mg | All lots | 2019-10-30 |
Dominion Pharmacal | Maximum Strength Acid Reducer Without Prescription (ranitidine) sold under the brand name Personnelle | 02407523 | 150 mg | All lots | 2019-10-25 |
Laboratoire Riva Inc. | Riva-Ranitidine 150 | 02247814 | 150 mg | All lots | 2019-10-25 |
Laboratoire Riva Inc. | Riva-Ranitidine 300 | 02247815 | 300 mg | All lots | 2019-10-25 |
Laboratoire Riva Inc. | Acid Reducer (ranitidine) sold under the brand names Biomedic, Circle K and Option+ | 02452464 | 75 mg | All lots | 2019-10-25 |
Pharmascience Inc. | PMS-Ranitidine 150 mg | 02242453 | 150 mg | All lots | 2019-10-25 |
Pharmascience Inc. | PMS-Ranitidine 300 mg | 02242454 | 300 mg | Al lots | 2019-10-25 |
Pharmascience Inc. | Acid Reducer (ranitidine) sold under the brand names Atoma, Biomedic, Compliments, Exact, Life Brand, London Drugs, Option+, Personnelle, Pharmasave, Preferred Pharmacy, Rexall and Selection | 02247551 | 75 mg | All lots | 2019-10-25 |
Pharmascience Inc. | Maximum Strength Acid Reducer Without Prescription (ranitidine) sold under the brand names Atoma, Biomedic, Compliments, Co-op Care+, Equate, Exact, Health One, Kirkland Signature, London Drugs, Option+, Personnelle, Pharmasave, Rexall and Selection | 02293471 | 150 mg | All lots | 2019-10-25 |
Pharmascience Inc. | Acid Reducer (ranitidine) sold under the brand names Exact and Life Brand | 02400103 | 150 mg | All lots | 2019-10-25 |
Vita Health Products Inc. | Acid Reducer (ranitidine) sold under the brand names Equate, iPharma, Stanley and Western Family | 02298740 | 75 mg | All lots | 2019-10-25 |
Vita Health Products Inc. | Maximum Strength Acid Reducer (ranitidine) sold under the brand names Equate, iPharma and Western Family | 02298902 | 150 mg | All lots | 2019-10-25 |
Sanofi Consumer Health Inc. | Zantac (ranitidine) | 02230287 | 75 mg | All lots | 2019-10-18 |
Sanofi Consumer Health Inc. | Zantac Maximum Strength Non-Prescription (ranitidine) | 02277301 | 150 mg | All lots | 2019-10-18 |
Sivem Pharmaceuticals ULC | Ranitidine | 02385953 | 150 mg | K46484 K46485 K48440 K48679 K50204 K50206 K50207 K50590 K50594 K50677 K50908 K50925 K50928 K50932 K50935 K51080 |
2019-10-18 |
Sivem Pharmaceuticals ULC | Ranitidine | 02385961 | 300 mg | K50624 K50941 K50947 K50950 |
2019-10-18 |
Teva Canada Limited | Act Ranitidine | 02248570 | 150 mg | All lots | 2019-10-18 |
Teva Canada Limited | Act Ranitidine | 02248571 | 300 mg | All lots | 2019-10-18 |
Apotex Inc. | Acid Reducer (ranitidine) sold under the brand names Equate and Selection | 02296160 | 150 mg | All lots | 2019-09-25 |
Apotex Inc. | Apo-Ranitidine Oral Solution | 02280833 | 15 mg/mL | All lots | 2019-09-25 |
Apotex Inc. | Apo-Ranitidine Tablet 150 mg | 00733059 | 150 mg | All lots | 2019-09-25 |
Apotex Inc. | Apo-Ranitidine Tablet 300 mg | 00733067 | 300 mg | All lots | 2019-09-25 |
Pro Doc Limitée | Ranitidine - 150 mg | 00740748 | 150 mg | All lots | 2019-09-25 |
Pro Doc Limitée | Ranitidine - 300 mg | 00740756 | 300 mg | All lots | 2019-09-25 |
Sanis Health Inc. | Ranitidine | 02353016 | 150 mg | All lots | 2019-09-25 |
Sanis Health Inc. | Ranitidine | 02353024 | 300 mg | All lots | 2019-09-25 |
Sivem Pharmaceuticals ULC | Ranitidine | 02385953 | 150 mg | NP4179 NP4183 NP4184 NP5656 NP5657 NT2721 NT2722 NT2724 NT2757 NT2762 NT2763 NT2764 NT2765 PJ2434 PJ2435 PV6243 PV6244 PV6245 |
2019-09-25 |
Sivem Pharmaceuticals ULC | Ranitidine | 02385961 | 300 mg | NP4177 NP4180 NT1365 PX8854 |
2019-09-25 |
Sandoz Canada | Sandoz Ranitidine | 02243229 | 150 mg | All lots | 2019-09-17 |
Sandoz Canada | Sandoz Ranitidine | 02243230 | 300 mg | All lots | 2019-09-17 |
Communications related to ranitidine recalls:
Nizatidine recalls
If you're taking a recalled nizatidine product, you should:
- Check the lot number on your nizatidine product, or contact your pharmacist, to determine whether any of your product is subject to this recall.
- Individuals taking a prescription nizatidine drug, including a recalled product, should not stop taking it unless they have spoken to their health care provider and obtained alternative treatment, as the risk of not treating the condition may be greater than the risk related to NDMA exposure
- Contact your health care provider if you have taken a nizatidine product and have concerns about your health.
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not impact Canadian products.
Some nizatidine products have been recalled due to the presence of nitrosamine impurities.
Company | Product Name | DIN | Strength | Lot | Expiry |
---|---|---|---|---|---|
Pendopharm Division of Pharmascience Inc. | AXID | 00778338 | 150mg | 616927 | 31-08-2020 |
Pendopharm Division of Pharmascience Inc. | AXID | 00778338 | 150mg | 617088 | 31-08-2020 |
Communications related to nizatidine recall:
Metformin recalls
Metformin
You should not stop taking your metformin drug without first discussing options with your health care provider. The risk of not having adequate diabetes treatment outweighs the risk from NDMA exposure.
Stopping metformin could lead to uncontrolled diabetes, which can cause some serious health problems.
For example, high blood sugars can result in:
- dizziness
- irritability
- drowsiness
- blurred vision
- unintended weight loss
- increased thirst and urination
- excessive hunger and fatigue
Very high blood sugars can also cause:
- vomiting
- diarrhea
- agitation
- confusion
- dehydration
- a coma
Longer-term health impacts include heart disease, nerve problems, kidney damage, blindness and amputations.
Contact your health care provider:
- to discuss treatment options if you're using a recalled product
- if you have taken a recalled product in the past and are concerned about your health
Some metformin products have been recalled due to the presence of, or potential for, nitrosamine impurities.
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not impact Canadian products.
Company | Product name | DIN | Strength | Lot | Expiry |
---|---|---|---|---|---|
Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3242 | 04/2020 |
Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3244 | 04/2020 |
Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3245 | 04/2020 |
Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3243 | 04/2020 |
Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3247 | 04/2020 |
Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | NV3248 | 04/2020 |
Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | PX5334 | 01/2021 |
Apotex Inc. | APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500 mg | PX5335 | 01/2021 |
Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269031 | 500 mg | AJY8006A | 05/2020 |
Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269031 | 500 mg | AJY8007A | 05/2020 |
Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269031 | 500 mg | AJY8005A | 05/2020 |
Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269031 | 500 mg | AJY8005B | 05/2020 |
Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269031 | 500 mg | AJY8008A | 05/2020 |
Ranbaxy Pharmaceuticals Canada Inc. | RAN-Metformin | 02269058 | 850 mg | AJZ8005A | 05/2020 |
JAMP Pharma | Metformin | 02380196 | 500 mg | X20283 | 11/2020 |
JAMP Pharma | Metformin | 02380196 | 500 mg | X20284 | 11/2020 |
JAMP Pharma | Metformin | 02380196 | 500 mg | X20286 | 11/2020 |
JAMP Pharma | Metformin | 02380196 | 500 mg | X20287 | 11/2020 |
JAMP Pharma | Metformin | 02380196 | 500 mg | X20288 | 11/2020 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y00225 | 12/2020 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y00226 | 12/2020 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y00227 | 12/2020 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y00228 | 01/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y00229 | 01/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y00230 | 01/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y00231 | 05/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y00232 | 05/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y01573 | 05/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y01574 | 05/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y01575 | 05/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y01576 | 05/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y01577 | 05/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y01578 | 05/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y01579 | 06/2021 |
JAMP Pharma | Metformin | 02380196 | 500 mg | Y01580 | 06/2021 |
JAMP Pharma | Metformin | 02380218 | 850 mg | X20385 | 07/2020 |
JAMP Pharma | Metformin | 02380218 | 850 mg | X20386 | 07/2020 |
JAMP Pharma | Metformin | 02380218 | 850 mg | X19224 | 10/2020 |
JAMP Pharma | Metformin | 02380218 | 850 mg | X19225 | 10/2020 |
JAMP Pharma | Metformin | 02380218 | 850 mg | X19226 | 10/2020 |
Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | PK3968 | 09/2020 |
Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | PK3969 | 09/2020 |
Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | PX5336 | 01/2021 |
Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | PY7174 | 02/2021 |
Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | PY7175 | 01/2021 |
Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | RF6463 | 06/2021 |
Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | RF6464 | 06/2021 |
Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | RF6465 | 06/2021 |
Apotex Inc | APO-METFORMIN ER (Metformin Hydrochloride Extended-Release Tablets) | 02305062 | 500mg | RF6466 | 06/2021 |
Communications related to metformin recalls:
- Health Canada evaluating NDMA in metformin drugs (December 5, 2019)
- Certain Metformin diabetes drugs recalled due to the presence or possible presence of NDMA (February 5, 2020)
Varenicline recalls
Varenicline
If you're taking a varenicline drug that has been recalled, you should:
- Continue taking your medication unless your health care provider has advised you to stop.
- Contact your health care provider:
- to discuss treatment options if you're using a recalled product
- if you have taken a recalled product in the past and are concerned about your health
Some varenicline products have been recalled due to the presence of, or potential for, nitrosamine impurities.
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not impact Canadian products. Recall is still outstanding for a single lot from Pfizer, please refer to the Dear Health Care Professional letter for more details.
Company | Product name | DIN | Strength | Lot | Expiry |
---|---|---|---|---|---|
Teva Canada Ltd. | TEVA-VARENICLINE TABLETS | 02426226 | 0.5mg | K60795 | 31/10/2021 |
Teva Canada Ltd. | TEVA-VARENICLINE TABLETS | 02426234 | 1mg | K60783 | 30/4/2021 |
Teva Canada Ltd. | TEVA-VARENICLINE TABLETS | 02426234 | 1mg | K60784 | 30/4/2021 |
Teva Canada Ltd. | TEVA-VARENICLINE COMBO TABLETS | 02426781 | 0.5mg/ 1mg | K60796 | 30/4/2021 |
Pfizer Canada ULC | CHAMPIX Tablet, Kit | 02298309 | 0.5mg and 1mg | 00019062 | 08/2021 |
Pfizer Canada ULC | CHAMPIX Tablet, Kit | 02298309 | 0.5mg and 1mg | 00020452 | 12/2021 |
Pfizer Canada ULC | CHAMPIX Tablet, Kit | 02298309 | 0.5mg and 1mg | 00020451 | 01/2022 |
Pfizer Canada ULC | CHAMPIX Tablet | 02291177 | 0.5mg | ED7397 | 05/2022 |
Communications related to varenicline recalls:
Orphenadrine recalls
Orphenadrine
If you're taking an orphenadrine drug that has been recalled, you should:
- Consider switching to an alternative medication
- Contact your health care provider:
- to discuss alternative treatment options
- if you have taken a recalled product in the past and are concerned about your health
Some orphenadrine products have been recalled due to the presence of or potential for nitrosamine impurities.
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not affect Canadian products.
Company | Product name | DIN | Strength | Lot | Expiry |
---|---|---|---|---|---|
SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 10025A18 | 06/2021 |
SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 10025B18 | 09/2021 |
SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 10025A19 | 11/2021 |
SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 36664 | 6/2021 |
SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 37342 | 9/2021 |
SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 37384 | 9/2021 |
SteriMax Inc. | OrfenAce tablets | 02047535 | 100 mg | 38058 | 11/2021 |
Sandoz Canada Inc. | Sandoz Orphenadrine tablets | 02243559 | 100 mg | JY6254 | 3/2022 |
Sandoz Canada Inc. | Sandoz Orphenadrine tablets | 02243559 | 100 mg | JY6255 | 3/2022 |
Communications related to orphenadrine recalls:
Amitriptyline recalls
Amitriptyline
If you're taking an amitriptyline drug that has been recalled, you should:
- Continue taking your medication as there is no immediate risk in continuing to take the recalled medication. Stopping amitriptyline may lead to mild withdrawal symptoms.
- Contact your health care provider:
- to discuss treatment options if you're using a recalled product
- if you have taken a recalled product in the past and are concerned about your health
Some amitriptyline products have been recalled due to the presence of or potential for nitrosamine impurities.
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not affect Canadian products.
Company | Product name | DIN | Strength | Lot | Expiry |
---|---|---|---|---|---|
Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | RF0410 | 05/2024 |
Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | PY1831 | 12/2023 |
Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | PY1832 | 12/2023 |
Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | PY1904 | 12/2023 |
AA Pharma Inc. | Elavil (Amitriptyline Hydrochloride Tablets USP) | 00335053 | 10 mg | PY1829 | 12/2023 |
AA Pharma Inc. | Elavil (Amitriptyline Hydrochloride Tablets USP) | 00335053 | 10 mg | PY1830 | 12/2023 |
AA Pharma Inc. | Elavil (Amitriptyline Hydrochloride Tablets USP) | 00335061 | 25 mg | PV0570 | 11/2023 |
AA Pharma Inc. | Elavil (Amitriptyline Hydrochloride Tablets USP) | 00335061 | 25 mg | PV0571 | 11/2023 |
Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | PY1833 | 12/2023 |
Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403137 | 10 mg | RM0518 | 11/2024 |
Apotex Inc. | APO-Amitriptyline (Amitriptyline Hydrochloride Tablets USP) | 02403145 | 25 mg | PV0569 | 11/2023 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 635484 | 04/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 638600 | 07/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 636906 | 07/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 636907 | 07/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 648428 | 04/2026 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 648429 | 04/2026 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 633439 | 01/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 632625 | 12/2023 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 632626 | 12/2023 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 633440 | 01/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 636905 | 07/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 636146 | 06/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 636749 | 07/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 634973 | 03/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654523 | 10 mg | 635485 | 04/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654515 | 25 mg | 635435 | 04/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654515 | 25 mg | 633433 | 01/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654515 | 25 mg | 632775 | 23/2023 |
Pharmascience Inc. | PMS- Amitriptyline | 00654515 | 25 mg | 635482 | 05/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654507 | 50 mg | 634972 | 03/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654507 | 50 mg | 635465 | 05/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654507 | 50 mg | 637195 | 08/2024 |
Pharmascience Inc. | PMS- Amitriptyline | 00654507 | 50 mg | 637532 | 09/2024 |
Pro Doc Limitée | Amitriptyline-10 | 00370991 | 10 mg | 632627 | 12/2023 |
Pro Doc Limitée | Amitriptyline-10 | 00370991 | 10 mg | 633441 | 01/2024 |
Pro Doc Limitée | Amitriptyline-10 | 00370991 | 10 mg | 638164 | 10/2024 |
Pro Doc Limitée | Amitriptyline-50 | 00456349 | 50 mg | 633436 | 01/2024 |
Communications related to amitriptyline recalls:
Propranolol recalls
Propranolol
If you're taking a propranolol drug that has been recalled, you should:
- Continue taking your medication unless you have been advised to stop by your health care provider as not treating your condition poses a greater health risk
- Contact your health care provider:
- to discuss treatment options if you're using a recalled product. While there are no other companies marketing extended release propranolol in Canada, immediate release propranolol products continue to be available, along with other treatment options.
- if you have taken a recalled product in the past and are concerned about your health
Some propranolol products have been recalled due to the presence of or potential for nitrosamine impurities.
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not affect Canadian products.
Company | Product name | DIN | Strength | Lot | Expiry |
---|---|---|---|---|---|
Pfizer Canada ULC | Inderal-LA capsules | 02042231 | 60 mg | EX7461 | 01/2024 |
Pfizer Canada ULC | Inderal-LA capsules | 02042231 | 60 mg | EH5907 | 08/2023 |
Pfizer Canada ULC | Inderal-LA capsules | 02042231 | 60 mg | DX6150 | 03/2023 |
Pfizer Canada ULC | Inderal-LA capsules | 02042258 | 80 mg | EX7462 | 01/2024 |
Pfizer Canada ULC | Inderal-LA capsules | 02042258 | 80 mg | EL1695 | 08/2023 |
Pfizer Canada ULC | Inderal-LA capsules | 02042258 | 80 mg | EE7221 | 05/2023 |
Pfizer Canada ULC | Inderal-LA capsules | 02042258 | 80 mg | DW8242 | 03/2023 |
Pfizer Canada ULC | Inderal-LA capsules | 02042258 | 80 mg | DJ2768 | 09/2023 |
Pfizer Canada ULC | Inderal-LA capsules | 02042266 | 120 mg | FE0541 | 01/2024 |
Pfizer Canada ULC | Inderal-LA capsules | 02042266 | 120 mg | EH5908 | 08/2023 |
Pfizer Canada ULC | Inderal-LA capsules | 02042266 | 120 mg | DX6159 | 03/2023 |
Pfizer Canada ULC | Inderal-LA capsules | 02042266 | 120 mg | DJ6820 | 09/2022 |
Pfizer Canada ULC | Inderal-LA capsules | 02042274 | 160 mg | FE6304 | 01/2024 |
Pfizer Canada ULC | Inderal-LA capsules | 02042274 | 160 mg | EH5906 | 08/2023 |
Pfizer Canada ULC | Inderal-LA capsules | 02042274 | 160 mg | DW8241 | 03/2023 |
Communications related to propranolol recalls:
Quinapril recalls
Quinapril
If you're taking a quinapril drug that has been recalled, you should:
- Continue taking your medication unless you have been advised to stop by your health care provider as not treating your condition may pose a greater health risk
- Contact your health care provider:
- to discuss treatment options if you're using a recalled product
- if you have taken a recalled product in the past and are concerned about your health
Some quinapril products have been recalled due to the presence of, or potential for, nitrosamine impurities.
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not affect Canadian products.
Company | Product name | DIN | Strength | Lot | Expiry |
---|---|---|---|---|---|
Pfizer Canada ULC | Accupril tablets | 01947672 | 10 mg | DY3042 | 03/2023 |
Pfizer Canada ULC | Accupril tablets | 01947672 | 10 mg | CK5285 | 05/2022 |
Pfizer Canada ULC | Accupril tablets | 01947680 | 20 mg | DT9592 | 03/2023 |
Pfizer Canada ULC | Accupril tablets | 01947680 | 20 mg | CK6258 | 05/2022 |
Pfizer Canada ULC | Accupril tablets | 01947680 | 20 mg | CK6259 | 05/2022 |
Pfizer Canada ULC | Accupril tablets | 01947699 | 40 mg | DT9591 | 03/2023 |
Pfizer Canada ULC | Accupril tablets | 01947699 | 40 mg | CM2828 | 05/2022 |
Pfizer Canada ULC | Accupril tablets | 01947699 | 40 mg | CM2829 | 05/2022 |
Pfizer Canada ULC | Accuretic tablets | 02237367 | 10/12.5 mg | FM9526 | 08/2023 |
Pfizer Canada ULC | Accuretic tablets | 02237367 | 10/12.5 mg | FA3736 | 07/2022 |
Pfizer Canada ULC | Accuretic tablets | 02237367 | 10/12.5 mg | EJ5192 | 07/2022 |
Pfizer Canada ULC | Accuretic tablets | 02237368 | 20/12,5 mg | EX4411 | 07/2022 |
Pfizer Canada ULC | Accuretic tablets | 02237368 | 20/12,5 mg | ET9511 | 07/2022 |
Pfizer Canada ULC | Accuretic tablets | 02237368 | 20/12,5 mg | EF3087 | 07/2022 |
Pfizer Canada ULC | Accuretic tablets | 02237369 | 20/25 mg | FA9224 | 07/2022 |
Pfizer Canada ULC | Accuretic tablets | 02237369 | 20/25 mg | EA0781 | 07/2022 |
Communications related to quinapril recalls:
Acyclovir recalls
Acyclovir
If you're taking an acyclovir drug that has been recalled, you should:
- Continue taking your medication unless you have been advised to stop by your health care provider as not treating your condition may pose a greater health risk.
- Talk to your health care provider if you are taking a recalled product and are concerned about your health.
Some acyclovir products have been recalled due to the presence of, or potential for, nitrosamine impurities.
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not affect Canadian products.
Company | Product Name | DIN | Strength | Lot | Expiry |
---|---|---|---|---|---|
Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | RH9369 | 08/2022 |
Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | TF4466 | 08/2024 |
Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | TE5062 | 06/2023 |
Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | TH6119 | 12/2023 |
Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | RH9368 | 08/2022 |
Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | RH9370 | 08/2022 |
Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | RP8516 | 07/2022 |
Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | RP8517 | 07/2022 |
Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | RT8943 | 07/2022 |
Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | TE5048 | 06/2024 |
Apotex Inc. | Apo-Acyclovir 200 mg | 02207621 | 200 mg | TK5832 | 05/2025 |
Apotex Inc. | Apo-Acyclovir 400mg | 02207648 | 400mg | TH6095 | 12/2023 |
Apotex Inc. | Apo-Acyclovir 400mg | 02207648 | 400mg | TH6096 | 12/2023 |
Apotex Inc. | Apo-Acyclovir 400mg | 02207648 | 400mg | TH6098 | 12/2023 |
Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | TK1734 | 05/2024 |
Apotex Inc. | Apo-Acyclovir 800 mg | 02207656 | 800 mg | TK3921 | 05/2024 |
Communications related to acyclovir recalls:
Duloxetine recalls
Duloxetine
If you're taking a duloxetine drug that has been recalled, you should:
- Continue taking your medication unless you have been advised to stop by your health care provider as not treating your condition may pose a greater health risk.
- Talk to your health care provider if you are taking a recalled product and are concerned about your health.
Some duloxetine products have been recalled due to the presence of nitrosamine impurities.
Products not on this list have not been recalled in Canada. Recalls taking place in other countries may not affect Canadian products.
Company | Product Name | DIN | Strength | Lot | Expiry |
---|---|---|---|---|---|
Pharmascience Inc. | PMS-Duloxetine | 02429446 | 30 MG | 646038 | 31/01/2025 |
Pharmascience Inc. | PMS-Duloxetine | 02429454 | 60 MG | 642678 | 30/04/2024 |
Pharmascience Inc. | PMS-Duloxetine | 02429454 | 60 MG | 645166 | 31/01/2025 |
Pharmascience Inc. | PMS-Duloxetine | 02429454 | 60 MG | 646571 | 31/01/2025 |
Sanis Health Inc. | Duloxetine | 02490897 | 60 MG | 644182 | 30/09/2024 |
Page details
- Date modified: